The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Evinacumab in Patients with Refractory Hypercholesterolemia
Open accessAbstract
BACKGROUND: Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known. METHODS: In this double-blind, placebo-controlled, phase 2 trial, we enrolled patients with or without heterozygous familial hypercholesterolemia who had refractory hypercholesterolemia, with a screening LDL cholesterol level of 70 mg per deciliter or higher with atherosclerosis or of 100 mg per deciliter or higher without atherosclerosis. Patients were randomly assigned to receive subcutaneous or intravenous evinacumab or placebo. The primary end point was the percent change from baseline in the LDL cholesterol level at week 16 with evinacumab as compared with placebo. RESULTS: In total, 272 patients were randomly assigned to the following groups: subcutaneous evinacumab at a dose of 450 mg weekly (40 patients), 300 mg weekly (43 patients), or 300 mg every 2 weeks (39 patients) or placebo (41 patients); or intravenous evinacumab at a dose of 15 mg per kilogram of body weight every 4 weeks (39 patients) or 5 mg per kilogram every 4 weeks (36 patients) or placebo (34 patients). At week 16, the differences in the least-squares mean change from baseline in the LDL cholesterol level between the groups assigned to receive subcutaneous evinacumab at a dose of 450 mg weekly, 300 mg weekly, and 300 mg every 2 weeks and the placebo group were -56.0, -52.9, and -38.5 percentage points, respectively (P<0.001 for all comparisons). The differences between the groups assigned to receive intravenous evinacumab at a dose of 15 mg per kilogram and 5 mg per kilogram and the placebo group were -50.5 percentage points (P<0.001) and -24.2 percentage points, respectively. The incidence of serious adverse events during the treatment period ranged from 3 to 16% across trial groups. CONCLUSIONS: In patients with refractory hypercholesterolemia, the use of evinacumab significantly reduced the LDL cholesterol level, by more than 50% at the maximum dose. (Funded by Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03175367.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another phase 2 trial studied evinacumab in 272 patients with refractory hypercholesterinaemia (either HeFH or established atherosclerosis). At a dose of 450 mg per week, evinacumab reduced LDL-C levels by − 56% compared with baseline [151].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [151]
Experimental — accuracy not yet measuredIn the citing paper
“In comparison, evinacumab, a monoclonal antibody against ANGPTL3 that is thought to cause near-total suppression of ANGPTL3 activity, 7,14,15 reduces ApoB levels by >40% in adults with refractory hypercholesterolemia or homozygous familial hypercholesterolemia in its intravenous formulation administered at a dose of 15 mg/kg.14,15”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citationKhera, A. V., Won, H.-H., Peloso, G. M., Lawson, K. S., Bartz, T. M., Deng, X., van Leeuwen, E. M., Natarajan, P., Emdin, C. A., Bick, A. G., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.520 · Cited by 942
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Self-citationEvacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Evinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 301
Gu, J., Sanchez, R. J., Chauhan, A., Fazio, S., & Rosenson, R. S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.001 · Cited by 6
Self-citationWeintraub, S. F., Schillow, J. A., Azari, B. M., & Hirsh, B. J. (2022) · JACC Case Reports · doi:10.1016/j.jaccas.2022.06.021 · Cited by 4
“Interestingly, we noted a 50% decrease in triglycerides with evinacumab therapy, which is not surprising given the role of ANGPTL3 in inhibiting triglyceride breakdown.(5,6) Ultimately, our patient required LDL-C apheresis, for which she sustained an excellent response, too.”
ResultFactoring in ANGPTL3 When LDL Is Refractory
Martin, S. S. (2020) · New England Journal of Medicine · doi:10.1056/nejme2032798 · Cited by 4
Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management
Ying, Q., Chan, D. C., & Watts, G. F. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000747 · Cited by 4
Lipid lowering therapies in chronic kidney disease: A call to action
Ruiz, J. M., Arroyo, D., de Cos, M., Fernández, M. R., Sánchez-Álvarez, E., Bores, P. G., Hernández, J. L., & Corral, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120563 · Cited by 4
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D. A., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 4
Self-citationReview of Lipid-Lowering Therapy in Women from Reproductive to Postmenopausal Years
Witting, C. S., Devareddy, A., & Rodríguez, F. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2305183 · Cited by 5
“patients with refractory HLD, evinacumab reduces LDLC by >50% [56,57].”
BackgroundZhang, H., Zhou, Z., Gu, J., Lin, Y., Yan, Y., Chen, X., Fan, M., & Huang, Y. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111282 · Cited by 4
Lipid-Targeted Atherosclerotic Risk Reduction in Older Adults: A Review
Hassen, L. J., Scarfone, S. R., & Milks, M. W. (2022) · Geriatrics · doi:10.3390/geriatrics7020038 · Cited by 3
“, LDL-C > 70 mg/dl with ASCVD, or >100 mg/dl without ASCVD [55].”
Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias
Watts, G. F., Chan, D. C., & Raal, F. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00027-3 · Cited by 3
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups
Wu, N., Li, Z.-F., Lu, M.-Y., & Li, J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2321374 · Cited by 3
Kong, X., He, G., Quan, X., Tan, Z., Yan, F., & Chen, X.-H. (2024) · Medicine · doi:10.1097/md.0000000000037637 · Cited by 3
“[17] Bempedoic acid is an ATP-citrate lyase inhibitor, which is a cytosolic enzyme upstream of 3-hydroxy-3-methylglutaryl coenzyme A in the pathway for de novo cholesterol synthesis.”
BackgroundOlatunji, G. D., Kokori, E., Moradeyo, A. A., Lema, K. F., Ayo, O. R., Obasanjo, O. M., Mustapha, M. J., Stanley, A. C., & Aderinto, N. (2024) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-024-00335-3 · Cited by 3
“The safety of subcutaneous evinacumab was investigated in 266 patients in a study by Rosenson et al. (2021) [24].”
BackgroundQin, R., Ye, L., Duan, L., Li, M., He, W., Mei, X., Li, D., Jin, R., Lv, C., Zhu, M., et al. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01539-8 · Cited by 3
“Common TEAEs of evinacumab were similar to those of SHR-1918, which included upper respiratory tract infection and influenza-like illness [16–18].”
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 3
New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance
Badimón, L. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab048 · Cited by 3
“I will start with the trial focussed in an innovative approach to lipidlowering using Evinacumab, a fully humanized monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3).(1) ANGPTL3 has a demonstrated role in lipoprotein metabolism, biochemically because it inhibits lipoprotein lipase and endothelial lipas…”
MethodANGPTL3 and ANGPTL8 in Thai subjects with hyperalphalipoproteinemia and severe hypertriglyceridemia
Kaewkrasaesin, C., Chatchomchuan, W., Muanpetch, S., & Khovidhunkit, W. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.08.059 · Cited by 3
Familial hypercholesterolaemia and emerging therapeutics
Farias, F. I., Kim, S. M., & Shapiro, M. D. (2023) · Heart · doi:10.1136/heartjnl-2022-321917 · Cited by 3
Gobeil, É., Bourgault, J., Mitchell, P. L., Houessou, U., Gagnon, É., Girard, A. S., Paulin, A., Manikpurage, H. D., Couture, C., Marceau, S., et al. (2023) · medRxiv · doi:10.1101/2023.05.29.23290580 · Cited by 3
White, O., Aligabi, Z., Burks, K. H., Tang, J., Stitziel, N. O., Goldberg, I. J., Remaley, A. T., & Lucero, D. (2025) · doi:10.1101/2025.03.02.640965 · Cited by 4
Klose, G., Gouni‐Berthold, I., & März, W. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01524-y · Cited by 2
Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent
Marston, N., & Zimerman, A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001013 · Cited by 3
Mombelli, G. G., Pavanello, C., Vicari, F., Moschetti, C., Albertí, A., Calabresi, L., & Sirtori, C. R. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.02.007 · Cited by 2
Watts, G. F., Scott, R., Sullivan, D., BAKER, J., Clifton, P. M., Hamilton, J., Given, B. D., Melquist, S., Zhou, R., Gaudet, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04307-8 · Cited by 3
Self-citationZadeh, S. S. T., Toth, P. P., & Banach, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789019 · Cited by 2
Bitencourt, I. C., Zimerman, A., & Marston, N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01441-z · Cited by 2
“While these data support a role for ANGPTL3 inhibition in selected patients with treatment-refractory HeFH, its use outside the HoFH indication remains off-label and awaits phase 3 testing [ 9].”
Feldman, D. I., Wu, K. C., Hays, A. G., Marvel, F. A., Martin, S. S., Blumenthal, R. S., & Sharma, G. V. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100181 · Cited by 2
Homozygous familial hypercholesterolaemia in a patient presenting with hypertensive encephalopathy
Maldar, S. B., & Pinto, C. J. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-250265 · Cited by 2
Management of lipid abnormalities in metabolic syndrome
Fariduddin, M. M., & Naik, R. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00048-7 · Cited by 2
Updates on Non-Statin LDL-Lowering Therapy
Abdulla, A., Shalaby, M., Kumfa, P. N., Raja, M. W., Allencherril, J., & Sharifeh, T. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02028-3 · Cited by 4
“In another trial by Rosenson and colleagues, evinacumab demonstrated similar LDL reduction in patients with HeFH with refractory LDL levels to standard therapies [28].”
OS TIPOS DE TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA E CONTROLE DOS TRIGLICERÍDEOS
Nogueira, D. R., Melo, G. C. D. C., Silva, I. D. A. C. E., Moreira, L. E. P., Pedrosa, M. D. S. B., Cardinali, M. D. P., Peron, P. L. V., & Piazzi, R. G. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p13 · Cited by 2
Afzal, M., Altaf, H., Faiz, T., Zafar, R., Shoukat, R., Waseem, M., & Aziz, S. (2024) · THE JOURNAL OF MICROBIOLOGY AND MOLECULAR GENETICS · doi:10.52700/jmmg.v5i1.145 · Cited by 2
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 4
Pechetty, R., Rao, P. S., Deb, T., Shekar, C., & Deepthi, K. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_55_2025 · Cited by 2
Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88608 · Cited by 2
Nuevos tratamientos en la dislipemia
de Isla, L. P., & Valdivielso, P. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.003 · Cited by 2
СУЧАСНА ГІПОЛІПІДЕМІЧНА ТЕРАПІЯ (ОГЛЯД ЛІТЕРАТУРИ)
Botsiurko, Y. V. (2022) · Прикарпатський вісник наукового товариства імені Шевченка ПУЛЬС · doi:10.21802/2304-7437-2022-18(66)-120-125 · Cited by 2
Guan, M., Wang, H., Wang, F., Liang, S., Li, L., Wang, B., & Zhang, L. (2024) · Thrombosis Journal · doi:10.1186/s12959-024-00657-w · Cited by 2
“Lomitapide lowers LDL-C by inhibiting microsomal triglyceride transfer protein (MTP), while evinacumab acts by inhibiting angi-opoietin-like 3 (ANGPTL3) [30, 31].”
BackgroundHyperlipidemia in Children and Adolescents
Michaud, L., Sharedalal, P., Seplowe, M., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000465 · Cited by 2
“This monoclonal antibody was also well studied for use in refractory hypercholesterolemia in young adults.(53)”
BackgroundZhang, P., Wang, K., Hu, T., Xu, M., You, X., Chen, M., Tang, X. L., Hu, H., Jiang, Y., Zhao, W., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202301564rr · Cited by 1
“17,78,79 In our study, it was observed that treatment with F1519-D95aA for 8 weeks not only potently reduced the serum TG and LDL-C levels, but also more effectively lowered the level of ApoB in serum than its parent F1519 and Evinacumab.”
BackgroundDigenic Overlap Syndrome Masquerading as Homozygous Familial Hypercholesterolemia
Maidman, S. D., Gurevitz, C., & Rosenson, R. S. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.104036 · Cited by 1
Self-citationBreaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia
Huang, S.-J., Huang, P. H., Song, N.-N., Jia, X.-H., Gao, H., Lu, Z., & Wen, X. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.105003 · Cited by 1
Yoo, J. H. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e19 · Cited by 2
“[11].”
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson, B., & Chan, P. (2025) · Biologics · doi:10.2147/btt.s500456 · Cited by 1
Krishnamurthy, S. S., Buzatto, A. Z., Campkin, C., Müller, H.-P., Wiesner, D., Weishaupt, J. H., Klose, V., Wiesenfarth, M., Elmas, Z., Herrmann, C., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04749-4 · Cited by 1
“The pattern of ANGPTL-3 and lipid profiles in ALS patients is consistent with the clinical experience on ANGPTL-3: a decrease in ANGPTL-3 and − 4 leads to a reduction in TG and cholesterol [22, 27].”
Myśliwiec, A., Leksa, D., Bartusik‐Aebisher, D., & Aebisher, D. (2026) · Journal of Applied Biomedicine · doi:10.32725/jab.2026.007 · Cited by 1
Review of Interventional Late Breaking Trials From AHA Scientific Sessions 2020 Virtual Meeting
Medranda, G. A., Case, B. C., Wermers, J. P., Morrison, N., Yerasi, C., Forrestal, B. J., Chezar‐Azerrad, C., & Waksman, R. (2021) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2021.02.020 · Cited by 1
“Harmony R. Reynolds, MD, of the New York University Grossman School of Medicine, presented the results of the HARP (Women's Heart Attack Research Program)-MINOCA study [8].”
Influential2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., & on behalf of Task Force Team for Familial Hypercholesterolemia, K. S. O. L. A. A. (2022) · Korean Journal of Medicine · doi:10.3904/kjm.2022.97.6.339 · Cited by 1
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development
Polychronopoulos, G., Kostourou, D.-T., & Τζιόμαλος, Κ. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2179480 · Cited by 1
“Evinacumab, at a dose of 300 or 450 mg weekly or 300 mg every 2 weeks administered subcutaneously, reduced LDL-C levels by 53, 56 and 38%, respectively, at 16 weeks [9].”
BackgroundInfluentialIndividualized dosing of evinacumab is predicted to yield reductions in drug expenses
ter Heine, R., Rongen, G. A. P. J. M., van Lennep, J. E. R., & Rutten, J. H. W. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.03.004 · Cited by 2
Modern prospects of targeted hypolipidemic therapy
Kuchmin, A. N., Борисович, Н. М., Grachev, A. M., & Смирнова, Е. В. (2023) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma321350 · Cited by 1
Lauzière, A., Brisson, D., Tremblay, G., Bédard, S., Khoury, É., & Gaudet, D. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.10.008 · Cited by 1
Self-citationSciahbasi, A., Russo, P., Zuccanti, M., Chiorazzo, L., Castelli, F., & Granatelli, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237420 · Cited by 1
“…statin plus Ezetimibe plus PCSK9 antibody [37] 85% Bempedoic acid plus Ezetimibe [41] 35% Evinacumab (Angiopoietin-like protein-3 inhibitor) [42] 50% Lomitapide [43] 50% Gene editing [44] 69% LDL-C L: low-density lipoprotein cholesterol, PCSK9: Proprotein convertase subtilisin/kexin type 9.”
Biologic therapy for dyslipidemia
Karásek, D. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.054 · Cited by 1
Xie, S., Galimberti, F., Olmastroni, E., Catapano, A. L., & Casula, M. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag230
Guideline recommendations, clinical trial data, and new and emerging therapies
Lindsley, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88607
Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte
Windler, E. E. T., Zyriax, B., & Augustin, M. (2021) · Gynäkologische Endokrinologie · doi:10.1007/s10304-021-00418-2
Efecto de la inhibición de la proteína símil angiopoyetina tipo 3 (ANGPTL3)
Elikir, G. D. (2021) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/revhospitalbaires.v41i3.108
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_9-1
Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte
Windler, E. E. T., Zyriax, B., & Augustin, M. (2022) · Journal für Gynäkologische Endokrinologie/Schweiz · doi:10.1007/s41975-022-00231-5
Arvanitis, M., Post, W. S., & Battle, A. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_3
Medikamentöse Therapie der Fettstoffwechselstörungen im Kindesalter
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_5
Les nouveaux traitements du cholestérol
Krempf, M. (2022) · Pratiques en nutrition · doi:10.1016/j.pranut.2022.09.004
Klose, G., Gouni‐Berthold, I., & März, W. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00178-9
Lipoprotein Apheresis for Reduction of Lipoprotein(a)
Julius, U., & Tselmin, S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_23
Overview of Lipids and Atherosclerosis
Libby, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00001-7
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_8
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_9
Kardiologisches Risikofaktormanagement: Rauchen, Übergewicht, Bewegung, Diät, Dyslipidämie
Lapp, H., Niepmann, S. T., & Becher, M. U. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21003-7.00002-9
Larouche, M., & Gaudet, D. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.009
Self-citationZhang, L., Li, B., Chen, W., Li, W., Yang, H., & Pan, D. (2024) · Research Square · doi:10.21203/rs.3.rs-4043847/v1
张, 卓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1451662
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia
Tomlinson, B., & Chan, P. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451752
“In another study in patients with refractory hypercholesterolemia, evinacumab was effective in reducing LDL-C by more than 50% at the maximum dose [66].”
Yang, Z., Xiao, W., Zhuang, Z., Zhan, S., Wang, M., Wu, Y., Huang, T., & Li, R. (2025) · PubMed Central · doi:10.6133/apjcn.202502_34(1).0004
“…pharmacological inactivation of ANGPTL3 with the monoclonal antibody evinacumab effectively reduces triglyceride and low-density lipoprotein-cholesterol (LDL-C) concentrations in patients with hypertriglyceridemia, 12 refractory hypercholesterolemia, 13 and homozygous familial hypercholesterolemia.”
Outland, E. H., Xin, Y., Dickson, A. L., Mundo, S., Tao, R., Zhong, X. Y., Karakoc, G., Serley, S., Jiang, L., Cox, N. J., et al. (2025) · medRxiv · doi:10.1101/2025.03.07.25323588
Immunotherapy for the Treatment of Atherosclerotic Disease: Integrative Review
Rodrigues, L. D. S., & Bertanha, M. (2025) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2025.0005
“16,17,36 In summary, Canakinumab represents an innovative therapy that explicitly targets IL-1 b to reduce in fl ammation in atherosclerosis and other cardiovascular diseases, potentially improving patient outcomes.”
InfluentialZhang, S., Zhao, J., Xie, X., Li, L., Chen, J., Liu, H., & Wang, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00732
Dziewierz, A., Bobrowska, B., Streb, W., Pelliccia, F., Bartuś, S., & Rajtar-Salwa, R. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2570839
“Evinacumab has been generally well-tolerated in clinical trials conducted to date [89–94].”
InfluentialZhong, C. X., Zhu, L., Liu, Y., Xu, B., & Kang, L. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39753
“In light of the convenience for patients, a double-blind, placebo-controlled, phase 2 trial was conducted to evaluate the safety and efficiency of evinacumab with subcutaneous and intravenous administration [33].”
Cardiovascular Risk Factor Dyslipidemia
Lebherz, C., & Lehrke, M. (2025) · Springer eBooks · doi:10.1007/978-3-662-69938-6_9
Schonck, W. A. M., Crosti, C., Marchesin, A., Gallo, A., Kayıkçıoğlu, M., Banach, M., Cuchel, M., Jones, R. E., Kainth, P., Catapano, A. L., et al. (2025) · European Atherosclerosis Journal · doi:10.56095/eaj.v4i3.115
Self-citationManagement and Therapy of Dyslipidemia
Marschang, P. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_23
Mikhailina, V. I., Zaicenoka, M., Meshkov, A. N., Блохина, А. В., Kiseleva, A. V., Limonova, A. S., Викторовна, К. О., Zharikova, A. A., Сотникова, Е. А., Pokrovskaya, M. S., et al. (2026) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2025-4665
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
“However, HDL-cholesterol was also lowered in patients receiving evinacumab, likely due to ANGPTL3 inhibition increasing the activity of endothelial lipase [127,128].”
Molecular genetic determinants of refractory hypercholesterolemia
Шестак, А. Г., Dorofeeva, O. D., Shirokova, N. S., & Иванощук, Д. Е. (2026) · Ateroscleroz · doi:10.52727/2078-256x-2026-22-1-84-98
Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial
Gill, R. D., Carpenter, M. A., Holstein, A., Garcia, A. R., Alkholder, A., Gupta, A., Singh, V., Quyyumi, A. A., Rasouli, N., Neeland, I. J., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101426 · Cited by 1
“Approximately one third of patients with diabetes will die of CVD despite the development of novel lipid lowering [5,6], anti-inflammatory [7,8], antithrombotic [9], dual antiplatelet [10], and novel glucose lowering medications [11,12].”
Majchrowicz, G., Jońca, M., Kurys, N., Piekarska, W., & Litke, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5095
Longer-term efficacy and safety of zodasiran in patients with mixed hyperlipidaemia
Rosenson, R. S., Gaudet, D., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., Leeper, N. J., Zhou, R., Aiyer, L., Hellawell, J. L., & Watts, G. F. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag376 · Cited by 1
Self-citationBajaj, A., McGuire, M., Shugg, S., Godin, R., & Underberg, J. A. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101790
Sophian, A. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107102
Damianaki, A., Stambolliu, E., Iliakis, P., Theofilis, P., Vakka, A., Kalliakouda, E., Patsalis, P., Konstantinidis, D., & Petras, D. I. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07934-y
Ruotolo, G., Harris, C., Lin, Y., Wilson, J. M., Pirro, V., Duffin, K. L., Thomas, M. K., Hartman, M. L., Neill, C. O., Coşkun, T., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71200
THE LATEST APPROACHES TO DYSLIPIDEMIA MANAGEMENT. A NARRATIVE REVIEW
Pawełkiewicz, S., Łysak, K., Fimiarz, K. J., Grygutis, I., Jarzęcka, U., Suchołbiak, A., Lachowski, F. R., Kozielec, M., Kozielec, K., & Górak, J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5647
Zhong, W., Zhang, J., Zhu, D., Pei, H., Wu, W., Huang, R., Yin, D., Gao, X., Li, B., Lv, C. Z., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.07.017 · Cited by 1
Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis
Masson, W. M., Lobo, M., MANSUR, M., Solís, C., & Nogueira, J. P. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03783-1
Hu, S., Guo, Z., Li, C., Nie, X., Wang, J., He, J., Zhuang, C., Zhang, L., Li, D., Lin, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0011
A Nutrient-Dependent ANGPTL3–PCSK9-Containing Complex in HepG2 Cells and Human Plasma
Bini, S., Pecce, V., Grimaldos, A. P., Costanzo, A. D., Minicocci, I., Covino, S., Tramontano, D., Piconese, S., D’Erasmo, L., & Arca, M. (2026) · Biomolecules · doi:10.3390/biom16101531
Shahid, R. S., Habib, S. M., Awan, M., Usman, M. A., & Mushtaq, M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.10.011
Metadata
- Authors
- Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., Son, V., & Gaudet, D.
- Affiliations
- Innsbruck Medical University (AT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-10
- Volume
- 383
- Issue
- 24
- Pages
- 2307-2319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3098138308
- Semantic Scholar
- ac311c54adb72af58fcfc75c3ae055aadb835e6b
- Cited by
- 302
- References
- 41
- Citations by year
- 2026: 27 · 2025: 45 · 2024: 52 · 2023: 55 · 2022: 55 · 2021: 65 · 2020: 3
- FWCI
- 40.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evinacumab, LDL cholesterol lowering, ANGPTL3, heterozygous familial hypercholesterolemia, atherosclerosis, subcutaneous administration, intravenous administration, monoclonal antibodies, lipid-lowering therapy, adverse events, dose comparison, treatment efficacy and safety, atherosclerotic cardiovascular disease
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adult, Antibodies, Monoclonal, Anticholesteremic Agents, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Female, Humans, Hyperlipoproteinemia Type II, Infusions, Intravenous, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
